Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Anna Blakney
University of British Columbia, Vancouver, BC, Canada
Dr Anna Blakney is an assistant professor and Tier 2 Canada Research Chair in the Michael Smith Laboratories and School of Biomedical Engineering at the University of British Columbia (UBC), Vancouver, BC, Canada. read more
Dr Blakney’s research background encompasses the development of molecular and biomaterial engineering strategies for delivery of self-amplifying RNA. Her lab uses bioengineering, molecular biology and immunology approaches to develop the next generation of RNA vaccines and therapies. Her research has been published in a variety of top tier journals including ACS Nano, Nature Communications, Molecular Therapy, Biomaterials, Journal of Controlled Release and Advanced Materials. Dr Blakney has received numerous awards and recognitions in addition to the Tier 2 Canada Research Chair in Nucleic Acid Bioengineering, including the 2022 Gairdner Early Career Investigator Award, the 2021 UBC President’s Award for Public Education Through Media and the 2022 Controlled Release Society Gene Delivery and Editing Focus Group Young Investigator Award.
Dr Anna Blakney discloses: Advisory board or panel fees from GenVax. Grants/research support from Pfizer and Replicate Bioscience. Contractual service fees from Moderna (Relationship Terminated).
Prof. Dr. med. Oliver Cornely
University of Cologne, Germany
Prof. Dr. med. Oliver Cornely is director and chair of Translational Research at the Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases at the University of Cologne, and scientific director of the Center for Clinical Trials. Clinically, he serves as infectious diseases consultant at the University Hospital of Cologne, Germany. read more
Prof. Dr. med. Cornely is board certified in internal medicine, infectious diseases, haematology, oncology and emergency medicine, and holds degrees in medical mycology and travel medicine. In January 2021, he founded the VACCELERATE platform, which currently includes 23 countries and 29 partner institutions for the European Commission to accelerate vaccine development against COVID-19 and future pandemic pathogens.
Prof. Dr. med. Cornely is immediate-past president of the European Confederation of Medical Mycology (ECMM), the umbrella organization of 28 national mycology societies. He set up the ECMM Global Guideline programme, ECMM Academy (Fellows programme), and ECMM Excellence Center Initiative, designating clinical and microbiological excellence centres after an international audit procedure. He is founder and chair of the Infectious Diseases Scientific Working Group of the European Hematology Association. Prof. Dr. med. Cornely is a member of the Council of the International Society for Human and Animal Mycology and serves as chair of the Infectious Diseases Working Party, a working group of the German Society for Hematology and Oncology. He was recently elected as site spokesman for Bonn/Cologne for the German Center for Infection Research.
Prof. Dr. med. Oliver Cornely discloses: Grant Research and Support from Amplyx, Basilea, BMBF, Cidara, DZIF, Gilead, Matinas, MedPace, MSD, Mundipharma, Pfizer and Scynexis. Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC and Pfizer. Speaker’s Bureau from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana, Hikma, MedUpdate, Merck/MSD, Mylan, Noscendo and United Medical/Knight. Expert testimony from Cidara. Data Safety Monitoring Board or Advisory Board from Actelion, Cidara, Entasis, IQVIA, Janssen, Med Pace, Paratek, Pulmocide and Shionogi. Other from DZIF – German Center for Infection Research.
Prof. Ann R Falsey
University of Rochester School of Medicine, New York, NY, USA
Prof. Ann R Falsey is a professor of medicine at the University of Rochester School of Medicine, New York, NY, USA. read more
Prof. Falsey is well established in clinical and translational research in the field of respiratory viral infections in adults, including: the epidemiology and impact of respiratory syncytial virus in adult populations, influenza, coronaviruses, parainfluenza viruses and human metapneumovirus. She has conducted numerous adult surveillance and vaccine studies in a variety of settings, including ambulatory older adult clinics, nursing homes and senior daycare centres. She has extensive experience in diagnostic and serologic assay development for respiratory viruses.
Prof. Falsey is a member of the steering committee for the Global Influenza Initiative, the Infectious Diseases Society of America and the American Virology Society. She has published over 200 peer-reviewed articles, reviews, book chapters and abstracts. She currently serves as the co-director for the National Institute of Allergy and Infectious Diseases Respiratory Pathogens Research Center recently awarded to the University of Rochester.Â
Prof. Ann R Falsey discloses: Advisory board or panel fees from Sanofi. Consultancy fees from Gilead. Grants/research support from BioFire Diagnostics, CyanVac, Janssen, Merck, Moderna and Pfizer.
